Alinvasive pulmonary aspergillosis in non-neutropenic patients: Analysis of a 14-month prospective clinical experience

Journal of Chemotherapy

Volumn 23, Issue 5, 2011, Pages 290-294

  Russo, A ^a   Falcone, M ^b   Vena, A ^a   Venditti, C ^b   Mancini, C ^b   Morelli, A ^a   Venditti, M ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antifungal therapy; Galactomannan; Invasive pulmonary aspergillosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT; GALACTOMANNAN; MANNAN; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CLINICAL ARTICLE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LUNG ASPERGILLOSIS; MALE; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; ASPERGILLUS; BLOOD; CLASSIFICATION; COMORBIDITY; HOSPITAL SUBDIVISIONS AND COMPONENTS; ISOLATION AND PURIFICATION; ITALY; LEUKOCYTE COUNT; METABOLISM; MICROBIOLOGY; MIDDLE AGED; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; COMORBIDITY; EARLY DIAGNOSIS; FEMALE; HOSPITAL UNITS; HOSPITALS, UNIVERSITY; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; ITALY; LEUKOCYTE COUNT; MALE; MANNANS; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 84857694182     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.5.290     Document Type: Article

References (26)

1. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707-717.
2. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-625.
3. Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol infect 2005; 11: 427-429.
4. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011; 49: 406-413.
5. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007; 30: 782-800.
6. De Pauw B, Walsh TJ, Donnelly JP, stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive Fungal infections Cooperative Group and the national institute of Allergy and infectious Diseases Mycoses study Group (EORTC/MsG) Consensus Group. Clin infect Dis 2008; 46: 1813-1821.
7. Cornillet A, Camus C, nimubona s Gandemer V, Tattevin P, Belleguic C et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey. Clin infect Dis 2006; 43: 577-584.
8. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin infect Dis 2002;34:7-14.
9. Walsh TJ, Shoham S, Petraitiene R, Sein T, Schaufele R, Kelaher A et al. Detection of galactomannan antigenemia in patients receiving piperacillin- tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug- antigen interaction. J Clin Microbiol 2004; 42:4744-4748.
10. Cornet M, Mallat H, Somme D, Guéot E, Kac G, Mainardi JL et al. Fulminant invasive pulmonary aspergillosis in immunocompetent patients-a two-case report. Clin Microbiol infect 2003; 9:1224-1227.
11. Denning DW. Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004; 170:580-581.
12. Petri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997; 23:317-325.
13. Peter E, Bakri F, Ball DM, Cheney RT, Segal BH. invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin infect Dis 2002; 35:e54-e56.
14. Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73:494-503.
15. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin infect Dis 1998; 26:1473-1455.
16. Carfagna P, Brandimarte F, Caccese R, Campagna D, Brandimarte C, Venditti M. Fatal invasive Pulmonary Aspergillosis Complicating influenza A (H1n1)v infection. Mycoses, on line early, 2011
17. Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, et al. Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1n1 infection. PLos One. 2011; 6:e19872.
18. Maris C, Martin B, Creteur J, Remmelink M, Piagnerelli M, Salmon I et al. Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch (2007) 450:329-333.
19. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34.
20. Nucci M, Noués A, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin infect Dis. 2010 1;51:1273-1280
21. Guinea J, Torres-narbona M, Gijòn P, Munoz P, Pozo F, Pelàez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol infect. 2010;16:870-877
22. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45:205-216.
23. Kwak EJ, Husain S, Obman A, Meinke L, Stout J, Kusne S, et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004;42:435-438.
24. Kimura SI, Odawara J, Aoki T, Yamakura M, Takeuchi M, Matsue K. Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. Int J Hematol 2009;90:463-470.
25. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: clinical practice guidelines of the infectious Diseases society of America. Clin Infect Dis 2008;46:327-360.
26. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009; 53: 5102-5107.